Q2 2026 13F · SEC CIK 1822947
Ally Bridge Group (NY) LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $77.6M
- Reported positions
- 23
- Top holdings a year, 3 yrs
- +31.3%
- Assets under management
- $218.9M
Ally Bridge Group (NY) LLC is a hedge fund that reported 23 positions worth $77.6M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Minerva Neurosciences Inc (NERV, 15.6%), Promis Neurosciences Inc (PMN, 10.5%), First Tracks Biotherapeutics (TRAX, 7.4%). A portfolio copying its top holdings returned 31.3% a year over the last 3 years, against 20.4% for the S&P 500.
Ally Bridge Group (NY) LLC holdings all 23 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| NERVMinerva Neurosciences Inc | 15.6% | +31.4% | $12.1M |
| PMNPromis Neurosciences Inc | 10.5% | +49.8% | $8.2M |
| TRAXFirst Tracks Biotherapeutics | 7.4% | — | $5.7M |
| AXSMAxsome Therapeutics, Inc. | 5.2% | — | $4.0M |
| ASMBAssembly Biosciences Inc. | 5.0% | — | $3.8M |
| AADIWhitehawk Therapeutics Inc | 4.8% | +0.0% | $3.7M |
| EWTXEdgewise Therapeutics Inc | 4.4% | -48.3% | $3.4M |
| CLYMClimb Bio Inc | 4.2% | — | $3.2M |
| KURAKura Oncology Inc | 4.1% | — | $3.2M |
| CTMXCytomx Therapeutics Inc. | 3.7% | -13.9% | $2.9M |
| AVTXAvalo Therapeutics Inc | 3.6% | — | $2.8M |
| PALIPalisade Bio Inc | 3.3% | — | $2.6M |
| SLDBSolid Bioscience Inc. | 3.3% | -66.6% | $2.6M |
| ANTXAn2 Therapeutics Inc | 3.3% | +0.0% | $2.5M |
| URGNUrogen Pharma Ltd | 3.3% | -65.8% | $2.5M |
| CATXPerspective Therapeutics Inc | 3.3% | -19.7% | $2.5M |
| IDYAIdeaya Biosciences Inc | 3.2% | — | $2.5M |
| IVAInventiva SA | 3.1% | -14.8% | $2.4M |
| ALMSAlumis Ord | 2.8% | -54.2% | $2.2M |
| OVIDOvid Therapeutics Inc | 2.2% | -77.8% | $1.7M |
| EPRXEupraxia Pharmaceuticals Inc | 2.1% | -61.8% | $1.7M |
| IBIOIbio Inc | 0.9% | — | $683K |
| TRAWTraws Pharma Inc | 0.9% | — | $663K |
What Ally Bridge Group (NY) LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- TRAX First Tracks Biotherapeutics7.4% of 13F
- AXSM Axsome Therapeutics, Inc.5.2% of 13F
- ASMB Assembly Biosciences Inc.5.0% of 13F
- CLYM Climb Bio Inc4.2% of 13F
- KURA Kura Oncology Inc4.1% of 13F
- AVTX Avalo Therapeutics Inc3.6% of 13F
- PALI Palisade Bio Inc3.3% of 13F
- IDYA Ideaya Biosciences Inc3.2% of 13F
Added to
- PMN Promis Neurosciences Inc+49.8% shares
- NERV Minerva Neurosciences Inc+31.4% shares
Reduced
- OVID Ovid Therapeutics Inc-77.8% shares
- SLDB Solid Bioscience Inc.-66.6% shares
- URGN Urogen Pharma Ltd-65.8% shares
- EPRX Eupraxia Pharmaceuticals Inc-61.8% shares
- ALMS Alumis Ord-54.2% shares
- EWTX Edgewise Therapeutics Inc-48.3% shares
- CATX Perspective Therapeutics Inc-19.7% shares
- IVA Inventiva SA-14.8% shares
Sold out
- PRAX Praxis Precision Medicines Iwas 10.5%
- SLNO Soleno Therapeutics Incwas 6.7%
- CMPS Compass Pathways PLCwas 5.7%
- TARS Tarsus Pharmaceuticals Incwas 5.6%
- ABVX Abivax SAwas 3.7%
- CAPR Capricor Therapeutics Incwas 3.4%
- IKT Inhibikase Therapeutics Incwas 2.2%
- RLMD Relmada Therapeutics Incwas 1.5%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +43.0% /yr
- S&P 500 +20.1%
- 3 years
- +31.3% /yr
- S&P 500 +20.4%
- 5 years
- +1.1% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $77.6M | 23 |
| Q1 2026 | $100.7M | 21 |
| Q4 2025 | $63.0M | 13 |
| Q3 2025 | $119.4M | 18 |
| Q2 2025 | $120.2M | 24 |
| Q1 2025 | $110.9M | 28 |
| Q4 2024 | $116.6M | 30 |
| Q3 2024 | $186.8M | 29 |
| Q2 2024 | $167.9M | 25 |
| Q1 2024 | $179.9M | 22 |
| Q4 2023 | $167.8M | 22 |
| Q3 2023 | $85.2M | 19 |
Questions about Ally Bridge Group (NY) LLC's portfolio
What stocks does Ally Bridge Group (NY) LLC own?
Ally Bridge Group (NY) LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 23 positions worth $77.6M. The largest are Minerva Neurosciences Inc (NERV) at 15.6%, Promis Neurosciences Inc (PMN) at 10.5%, First Tracks Biotherapeutics (TRAX) at 7.4%, Axsome Therapeutics, Inc. (AXSM) at 5.2% and Assembly Biosciences Inc. (ASMB) at 5.0%.
What did Ally Bridge Group (NY) LLC buy last quarter?
In Q2 2026, Ally Bridge Group (NY) LLC added a new position in First Tracks Biotherapeutics (TRAX), a new position in Axsome Therapeutics, Inc. (AXSM), a new position in Assembly Biosciences Inc. (ASMB), a new position in Climb Bio Inc (CLYM), a new position in Kura Oncology Inc (KURA), Promis Neurosciences Inc (PMN) (+49.8% shares) and Minerva Neurosciences Inc (NERV) (+31.4% shares), compared with its Q1 2026 filing.
What did Ally Bridge Group (NY) LLC sell last quarter?
In Q2 2026, Ally Bridge Group (NY) LLC sold all of Praxis Precision Medicines I (PRAX), sold all of Soleno Therapeutics Inc (SLNO), sold all of Compass Pathways PLC (CMPS), sold all of Tarsus Pharmaceuticals Inc (TARS), sold all of Abivax SA (ABVX), Ovid Therapeutics Inc (OVID) (-77.8% shares), Solid Bioscience Inc. (SLDB) (-66.6% shares) and Urogen Pharma Ltd (URGN) (-65.8% shares), compared with its Q1 2026 filing.
How has Ally Bridge Group (NY) LLC's portfolio performed?
A portfolio copying Ally Bridge Group (NY) LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +31.3% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +43.0% against +20.1%. Over 5 years: +1.1% a year against +11.6%.
When is Ally Bridge Group (NY) LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Ally Bridge Group (NY) LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Ally Bridge Group (NY) LLC manage?
Ally Bridge Group (NY) LLC reported $218.9M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $77.6M.